Alliance for Clinical Trials in Oncology shared a post on X:
“New Trial!
Ada Waks of Dana-Farber Cancer Institute leads Alliance for Clinical Trials in Oncology A012303 (ShortStop-HER2), a study exploring if less treatment is needed after surgery for people with early-stage HER2+ breast cancer who had no cancer left after chemo + HER2 therapy (before surgery).”
Sarah Sammons, Associate Director of the Metastatic Breast Cancer Program at Dana-Farber Cancer Institute, shared Alliance for Clinical Trials in Oncology‘s post, adding:
“This is where the importance of government cancer funding comes in.
My brilliant colleague designing a large trial to give less trastuzumab to HER2+ patients who achieve pCR.”
More posts featuring Breast Cancer.